アタマジラミ感染症治療薬の世界市場規模：薬剤タイプ別、剤形別、作用機序別、地域範囲別、予測

アタマジラミ感染症治療薬の市場規模と予測

アタマジラミ感染症治療薬の市場規模は、2024年には1億3,704万米ドルと評価され、2026年から2032年にかけてCAGR 6.26%で成長し、2032年には2億2,275万米ドルに達すると予測されています。

• アタマジラミ感染症治療薬は、一般にアタマジラミとして知られるアタマジラミの蔓延を治療・駆除するための薬剤です。これらの治療薬は通常、シャンプー、ローション、クリームなどの外用剤の形で提供され、シラミを殺すか、シラミの繁殖能力を阻害する有効成分が含まれています。
• アタマジラミ感染症治療薬の主な用途は、アタマジラミに感染した人を直接治療することです。これには、薬用シャンプー、ローション、クリームを頭皮や毛髪に塗布することが含まれます。
• また、学校や保育施設など、アタマジラミの感染リスクが高い環境では、予防的に使用できる薬剤や治療法もあります。
• アタマジラミ感染症治療薬の将来は、より効果的で安全な治療法の開発にあります。これには、現在の治療で見られる耐性に対抗できる新しい有効成分の研究と導入が含まれます。

世界のアタマジラミ感染症治療薬市場力学

世界のアタマジラミ感染症治療薬市場を形成している主な市場力学は以下の通りである：

主な市場促進要因

• 有病率の増加：特に学齢期の子供の間でアタマジラミの発生率が上昇しており、効果的な治療オプションに対する需要が高まっています。人口密集地での感染率の高さが、このニーズをさらに高めています。米国疾病対策予防センター（CDC）によると、2024年現在、米国では3歳から11歳の子どもの間で毎年600万～1,200万人のアタマジラミが発生していると推定されています。この高い罹患率が引き続き市場の需要を牽引しています。
• 認識と教育：アタマジラミ感染の治療の重要性に関する認識と教育キャンペーンの高まりが市場成長に寄与しています。保護者、学校、ヘルスケアプロバイダーは、感染症に迅速に対処するよう警戒を強めています。
• 革新的な製品開発：製薬業界における継続的な研究開発により、先進的でより効果的なアタマジラミ治療薬の導入が進んでいます。無害で使いやすい製剤などのイノベーションが消費者を惹きつけています。例えば、2024年2月、アーバー・ファーマシューティカルズは、神経毒性のない新しいアタマジラミ治療薬の第3相臨床試験の成功を発表しました。この技術革新は、シラミ集団における殺虫剤耐性に関する懸念に対処するものです。
• 規制当局の承認：新しい治療法に対する規制当局の承認と支援は、市場の成長を促進します。効果的で安全なアタマジラミ治療薬の承認プロセスが合理化されたことで、製薬企業のこの市場への投資が促進されます。
• 世界市場の拡大：新興市場におけるヘルスケアインフラの拡大と市販薬へのアクセスが、アタマジラミ感染症治療薬市場を押し上げます。また、流通チャネルの拡大やオンライン小売も、製品の幅広い入手を促進しています。世界保健機関（WHO）は、2024年に発表した「顧みられない熱帯病に関する報告書」の中で、アタマジラミ感染症は世界の子どもの最大20%が罹患しており、発展途上国ではその割合が高いと推定しています。この世界の蔓延が市場拡大を後押ししています。

主な課題

• 薬剤耐性：一般的に使用されているアタマジラミ治療薬に対する耐性開発が大きな阻害要因となっています。これにより、既存製品の効力が低下し、蔓延の抑制や治療が困難になります。2024年3月にJournal of Medical Entomology誌に発表された研究によると、米国では約98％のアタマジラミが、市販のシラミ治療薬で最も一般的な有効成分であるピレスロイドに耐性を持っていました。この高い耐性率は治療効果に大きく影響します。
• 副作用：一部のアタマジラミ治療薬には、皮膚刺激やアレルギー反応などの副作用が伴う可能性があり、使用を躊躇させることがあります。特に小児に対する安全性への懸念が、市場の成長を制限しています。FDA Adverse Event Reporting System（FAERS）は、2024年の年次サマリーで、アタマジラミ治療に関連した副作用の症例数は1,200例で、皮膚刺激が最も多かったと報告しています。これは前年比15％増です。
• 認識不足：アタマジラミとその治療法に関する不十分な認識と誤解が、市場の成長を妨げています。多くの人が効果のない家庭療法に頼ったり、治療を完全に怠ったりしています。CDCの2024年健康情報動向調査（HINTS）では、回答者の65％しか効果的なアタマジラミの治療法を正しく認識できておらず、知識のギャップが大きいことが明らかになっています。
• 文化的スティグマ：アタマジラミ感染に伴う社会的スティグマ（烙印）や恥ずかしさは、適切な治療を受けることを妨げます。この文化的障壁は、市場への浸透やアタマジラミ感染症治療薬の全体的な需要に影響を与えます。

主要動向

• 自然で無害な治療へのシフト：天然で無害な製品を好む消費者の増加が、植物成分から作られたアタマジラミ治療薬の開発を促進しています。これらの製品は、特に子供や敏感な人に対する安全性プロファイルが支持されています。
• 教育キャンペーン：政府、ヘルスケア組織、公開会社は、アタマジラミの予防と治療について一般の人々を啓蒙するキャンペーンを実施しています。このような取り組みにより、知識が向上し、感染にまつわるスティグマが軽減され、治療に対する需要が増加しています。
• カスタマイズされた治療ソリューション：敏感な頭皮のための治療や、繰り返し使用するのに適した製品など、特定のニーズに対応するように設計された製品により、個別化された的を絞った治療が人気を集めています。このようなカスタマイズは、ユーザーの満足度を高め、市場の成長を促進します。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 アタマジラミ感染症治療薬市場：薬剤タイプ別

• 処方薬
• 一般用医薬品

第5章 アタマジラミ感染症治療薬市場：剤形別

• 局所治療薬
• 経口薬

第6章 アタマジラミ感染症治療薬市場：作用機序別

• 神経毒性剤
• 物理的薬剤
• 併用療法

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Bayer
• Perrigo
• Pfizer
• GlaxoSmithKline
• Prestige Brands
• Alliance Pharmaceuticals
• Teva Pharmaceuticals
• Arbor Pharmaceuticals
• ParaPRO LLC
• Encube Ethicals
• Foamix Pharmaceuticals
• Oystershell Consumer Health
• Thornton and Ross
• Tianren

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Head Lice Infestation Drug Market Size And Forecast

Head Lice Infestation Drug Market size was valued at USD 137.04 Million in 2024 and is projected to reach USD 222.75 Million by 2032, growing at a CAGR of 6.26% from 2026 to 2032.

• Head lice infestation drugs are medications designed to treat and eliminate infestations of Pediculus humanus capitis, commonly known as head lice. These drugs typically come in the form of topical treatments such as shampoos, lotions, and creams, which contain active ingredients that either kill the lice or inhibit their ability to reproduce.
• The primary application of head lice infestation drugs is the direct treatment of individuals infested with head lice. This includes the application of medicated shampoos, lotions, and creams to the scalp and hair.
• Some drugs and treatments can also be used as a preventive measure in environments where the risk of head lice infestation is high, such as schools and childcare facilities.
• The future of head lice infestation drugs lies in the development of more effective and safer treatments. This includes the research and introduction of new active ingredients that can combat resistance seen with current treatments.

Global Head Lice Infestation Drug Market Dynamics

The key market dynamics that are shaping the global head lice infestation drug market include:

Key Market Drivers

• Increasing Prevalence: The rising incidence of head lice infestations, particularly among school-aged children, drives demand for effective treatment options. High rates of infestation in densely populated areas further amplify this need. According to the Centers for Disease Control and Prevention (CDC), as of 2024, an estimated 6-12 million head lice infestations occur each year among children 3 to 11 years of age in the United States. This high incidence rate continues to drive market demand.
• Awareness and Education: Growing awareness and educational campaigns about the importance of treating head lice infestations contribute to market growth. Parents, schools, and healthcare providers are increasingly vigilant in addressing infestations promptly.
• Innovative Product Development: Continuous research and development in the pharmaceutical industry lead to the introduction of advanced and more effective head lice treatment products. Innovations such as non-toxic and easy-to-use formulations attract consumers. For instance, in February 2024, Arbor Pharmaceuticals announced the successful Phase III clinical trials of a new, non-neurotoxic head lice treatment. This innovation addresses concerns about pesticide resistance in lice populations.
• Regulatory Approvals: Favorable regulatory approvals and support for new treatments enhance market growth. Streamlined approval processes for effective and safe head lice medications encourage pharmaceutical companies to invest in this market.
• Global Market Expansion: Expanding healthcare infrastructure and access to over-the-counter treatments in emerging markets boost the head lice infestation drug market. Increased distribution channels and online retailing also facilitate wider product availability. The World Health Organization (WHO) estimated in its 2024 report on neglected tropical diseases that head lice infestations affect up to 20% of children worldwide, with higher rates in developing countries. This global prevalence supports market expansion.

Key Challenges:

• Drug Resistance: The development of resistance to commonly used head lice treatments poses a significant restraint. This reduces the efficacy of existing products, making infestations harder to control and treat. According to a study published in the Journal of Medical Entomology in March 2024, approximately 98% of head lice in the United States were resistant to pyrethroids, the most common active ingredient in over-the-counter lice treatments. This high resistance rate significantly impacts treatment efficacy.
• Side Effects: Potential side effects associated with some head lice treatments, such as skin irritation and allergic reactions, can deter use. Concerns over safety, especially for children, limit market growth. The FDA Adverse Event Reporting System (FAERS) reported in its 2024 annual summary that there were 1,200 cases of adverse reactions related to head lice treatments, with skin irritation being the most common complaint. This represents a 15% increase from the previous year.
• Lack of Awareness: Inadequate awareness and misconceptions about head lice and their treatment methods hinder market growth. Many individuals may resort to ineffective home remedies or neglect treatment altogether. The CDC's 2024 Health Information National Trends Survey (HINTS) revealed that only 65% of respondents could correctly identify effective head lice treatment methods, indicating a significant knowledge gap.
• Cultural Stigma: Social stigma and embarrassment associated with head lice infestations can prevent individuals from seeking proper treatment. This cultural barrier affects market penetration and the overall demand for head lice infestation drugs.

Key Trends

• Shift towards Natural and Non-Toxic Treatments: Increasing consumer preference for natural and non-toxic products is driving the development of head lice treatments made from botanical ingredients. These products are favored for their safety profiles, particularly for children and sensitive individuals.
• Educational Campaigns: Governments, healthcare organizations, and companies are conducting awareness campaigns to educate the public about head lice prevention and treatment. These initiatives are improving knowledge and reducing the stigma associated with infestations, thereby increasing the demand for treatments.
• Customized Treatment Solutions: Personalized and targeted treatments are becoming more popular, with products designed to address specific needs, such as treatments for sensitive scalps or products suitable for repeated use. This customization enhances user satisfaction and market growth.

Global Head Lice Infestation Drug Market Regional Analysis

Here is a more detailed regional analysis of the global head lice infestation drug market:

North America

• North America is expected to dominate the global head lice infestation drug market. North America accounted for approximately 40% of the global head lice treatment market in 2024, with the United States being the largest contributor. Major drivers of the market are high awareness, advanced healthcare infrastructure, and proactive public health initiatives. As of 2024, the U.S. healthcare spending reached $4.5 trillion, representing 18.2% of GDP, according to the Centers for Medicare & Medicaid Services (CMS). This robust healthcare infrastructure supports advanced treatment options and distribution networks for head lice products.
• Increased prevalence of head lice among school-aged children, high disposable income, and strong presence of major pharmaceutical companies.
• Emphasis on innovative and non-toxic treatments, widespread use of over-the-counter products, and robust online retailing. E-commerce sales of over-the-counter head lice treatments in North America grew by 25% in 2024 compared to the previous year, according to a report from a leading market research firm.

Asia Pacific

• The Asia Pacific region is experiencing rapid growth in the head lice infestation drug market, fueled by a large population and increasing healthcare expenditure. The Asian Development Bank's 2024 report on healthcare in Asia showed that healthcare spending in the region increased by an average of 8% annually over the past five years, supporting growth in various healthcare markets, including head lice treatments.
• High prevalence of head lice, growing middle class with rising disposable income, and improving access to healthcare products. The World Health Organization's Western Pacific Regional Office reported in their 2024 annual health survey that approximately 15-20% of primary school children in the region experience head lice infestations annually.
• Expansion of e-commerce platforms, introduction of affordable treatment options, and growing awareness through educational initiatives. A study published by the Journal of Medical Internet Research in February 2024 found that online sales of over-the-counter medications, including head lice treatments, grew by 35% in Asia Pacific countries in 2024 compared to the previous year.

Global Head Lice Infestation Drug Market: Segmentation Analysis

The Global Head Lice Infestation Drug Market is segmented based on Type of Drug, Formulation, Mode of Action, And Geography.

Head Lice Infestation Drug Market, By Type of Drug

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

Based on Type of Drug, the Global Head Lice Infestation Drug Market is bifurcated into Prescription Drugs and Over-the-Counter (OTC) Drugs. In the head lice infestation drug market, the over-the-counter (OTC) drugs segment is currently dominating, driven by the widespread availability, ease of access, and immediate need for treatment without the requirement for a prescription. OTC products, such as shampoos and lotions, are popular among consumers for their convenience and effectiveness. According to a report by the Consumer Healthcare Products Association (CHPA) released in January 2024, OTC head lice treatments accounted for approximately 75% of the total head lice treatment market in North America in 2024. Meanwhile, the prescription drugs segment is experiencing rapid growth, fueled by the increasing incidence of treatment-resistant lice and the need for more potent solutions that require medical oversight. As resistance to OTC treatments rises, prescription medications are becoming an essential alternative for more severe or persistent infestations.

Head Lice Infestation Drug Market, By Formulation

• Topical Treatments
• Oral Medications

Based on Formulation, the Global Head Lice Infestation Drug Market is bifurcated into Topical Treatments, and Oral Medications. In the head lice infestation drug market, the topical treatments segment is currently dominating due to its established effectiveness, ease of application, and immediate action on lice and nits. According to a report by the American Journal of Managed Care published in December 2024, topical treatments accounted for approximately 80% of the global head lice treatment market in 2024. Products like shampoos, lotions, and creams are widely preferred for their direct application to the affected area. On the other hand, the oral medications segment is the rapidly growing segment, driven by the need for alternative treatments amid increasing resistance to topical treatments. Oral medications offer systemic treatment options, making them an effective choice for severe or resistant cases of head lice infestation.

Head Lice Infestation Drug Market, By Mode of Action

• Neurotoxic Agents
• Physical Agents
• Combination Therapies

Based on Mode of Action, the Global Head Lice Infestation Drug Market is bifurcated into Neurotoxic Agents, Physical Agents, and Combination Therapies. In the head lice infestation drug market, the neurotoxic agents segment is currently dominating, owing to its long-standing use and proven efficacy in killing lice by targeting their nervous system. According to a report by the American Academy of Dermatology published in November 2024, neurotoxic agents accounted for approximately 65% of the global head lice treatment market in 2024.These treatments are widely available and have been the go-to solution for many years. However, the combination therapies segment is rapidly growing, driven by the increasing resistance to neurotoxic agents and the need for more comprehensive treatment approaches. Combination therapies, which integrate multiple modes of action such as chemical and mechanical removal methods, are gaining popularity for their enhanced effectiveness in treating resistant lice infestations.

Head Lice Infestation Drug Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Head Lice Infestation Drug Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the head lice infestation drug market, North America is the dominating segment, driven by high awareness, advanced healthcare infrastructure, and proactive public health initiatives. The region's strong presence of major pharmaceutical companies and widespread use of over-the-counter treatments also contribute to its leading position. Meanwhile, the Asia Pacific segment is rapidly growing, fueled by a large population, increasing healthcare expenditure, and improving access to head lice treatments. Rising awareness through educational campaigns and the expansion of e-commerce platforms are further propelling market growth in this region.

Key Players

The "Global Head Lice Infestation Drug Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bayer, Perrigo, Pfizer, GlaxoSmithKline, Prestige Brands, Alliance Pharmaceuticals, Teva Pharmaceuticals, Arbor Pharmaceuticals, ParaPRO LLC, Encube Ethicals, Foamix Pharmaceuticals, Oystershell Consumer Health, Thornton and Ross, Tianren.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Head Lice Infestation Drug Market Key Developments

• In October 2021, Teva Pharmaceuticals launched a new prescription head lice treatment called "AirAlle". This treatment uses a combination of heated air and a topical solution to effectively kill lice and their eggs.
• In March 2022, Bayer AG expanded its product line with a new over-the-counter head lice treatment, "Nix Ultra", which is designed to address resistance issues and provide a more effective solution for persistent infestations.
• In July 2022, Johnson & Johnson introduced "LiceMD", a non-toxic, pesticide-free head lice treatment that utilizes a silicone-based formula to suffocate lice and their eggs. This product aims to provide a safer alternative to traditional neurotoxic agents.
• In September 2022, Prestige Consumer Healthcare acquired the rights to the "Rid" brand of head lice treatments. This strategic acquisition is expected to strengthen their portfolio of consumer healthcare products and expand their market presence.
• In February 2024, Perrigo Company launched an advanced lice comb called "V-Combing". This device uses micro-vibration technology to enhance the removal of lice and nits, offering a mechanical solution that can be used in conjunction with chemical treatments.
• In May 2024, L'Oreal entered the head lice treatment market with the introduction of "LiceGuard", a botanical-based shampoo that claims to be effective against resistant lice strains and gentle on the scalp.

TABLE OF CONTENTS

1. INTRODUCTION

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Head Lice Infestation Drug Market, By Type of Drug

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

5. Head Lice Infestation Drug Market, By Formulation

• Topical Treatments
• Oral Medications

6. Head Lice Infestation Drug Market, By Mode of Action

• Neurotoxic Agents
• Physical Agents
• Combination Therapies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Bayer
• Perrigo
• Pfizer
• GlaxoSmithKline
• Prestige Brands
• Alliance Pharmaceuticals
• Teva Pharmaceuticals
• Arbor Pharmaceuticals
• ParaPRO LLC
• Encube Ethicals
• Foamix Pharmaceuticals
• Oystershell Consumer Health
• Thornton and Ross
• Tianren

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References